バルサルタンによる全身右心室機能に対する効果: ダブルブラインド,ランダム化,プラセボ対照試験
Teun van der Bom1, Michiel M Winter, Berto J Bouma
1Department of Cardiology, Academic Medical Center, Amsterdam, Netherlands.
Circulation
|December 19, 2012
まとめ
バルサルタンは,大動脈の転移を患った患者の全身右心室射出分子を改善しませんでした. しかし,バルサタン治療は3年間にわたって右心室の体積と質量の増加を減少させた.
科学分野:
- 心臓病学 心臓病学
- クリニック・トライアル 臨床試験
- 薬理学 薬理学とは
背景:
- システム性右心室の患者におけるアンジオテンシンII受容体阻害剤 (ARB) の有効性は不明である.
- 大動脈の転移 (TGA) は,有意な臨床的影響を伴う状態である全身右心室を引き起こす可能性があります.
研究 の 目的:
- システム性右心室疾患の患者の管理におけるARBバルサータンの役割を調査する.
- TGA患者におけるヴァルサルタンによる右心室機能,運動能力,および生活の質への影響を評価する.
主な方法:
- 多センター,ダブルブラインド,ランダム化制御試験で,TGAによる全身性右心室疾患の88人の患者が参加した.
- 患者は,バルサタン160mgを1日2回,またはプラセボを3年間投与された.
- 主要エンドポイント:心血管磁気共鳴画像またはマルチローウ検出器コンピュータトモグラフィーで評価された右心室放出分数の変化.
主要な成果:
- 3年間のヴァルサタン治療は,全身右心室噴出分数,運動能力,または生活の質に有意な効果を示さなかった.
- バルサルタンはプラセボと同様の安全性プロファイルと関連しており,深刻な有害事象は報告されていません.
- プラセボと比較して,ヴァルサルタン群では,右心室の終末ダイアストリック体積と質量の有意に小さい増加が観察されました.
結論:
- バルサルタンは,右心室排泄分数,運動能力,または全身右心室を有する患者の生活の質に重大な利点を提供していません.
- バルサルタンは,右心室の体積と質量の増加を緩和する好ましい効果を示した.
- この研究では,ヴァルサルタンが,この患者集団における心室リモデルの管理における潜在的な役割を示唆しています.
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...